8-K
filed June 4, 2026, 4:05 PM ET
ticker KURA
CIK 0001422143
other material
confidence high
sentiment neutral
materiality 0.60
Kura Oncology stockholders approve 6.5M share increase for equity plan and 2.5M for ESPP at annual meeting
Kura Oncology, Inc.
- Stockholders approved amendment to 2014 Equity Incentive Plan, increasing authorized shares by 6.5 million.
- Stockholders approved amendment to 2015 ESPP, increasing authorized shares by 2.5 million.
- Elected three Class III directors: Diane Parks, Mary T. Szela, and Michael J. Vasconcelles, M.D. to terms expiring 2029.
- Ratified Ernst & Young as independent auditor for FY2026; 69.4M for, 140.8K against.
- Advisory Say-on-Pay approved (48.8M for, 1.1M against); board set future votes every year.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Kura Oncology, Inc. shareholders approved Advisory Indication on Frequency of Stockholder Advisory Votes on Executive Compensation at the 2026-06-04 meeting.
- Proposal
- say on pay frequency
- Outcome
- passed
- Meeting
- 2026-06-04
Exact text from the filing
Proposal 4. Advisory Indication on Frequency of Stockholder Advisory Votes on Executive Compensation 1 Year 2 Years 3 Years Abstain Broker Non-Votes 48,362,762 54,055 1,586,672 8,677,543 11,097,548
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Kura Oncology, Inc. shareholders approved Approval of our Amended ESPP at the 2026-06-04 meeting.
- Proposal
- equity plan
- Outcome
- passed
- Meeting
- 2026-06-04
Exact text from the filing
Proposal 6. Approval of our Amended ESPP For Against Abstain Broker Non-Votes 58,306,174 213,434 161,424 11,097,548
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Kura Oncology, Inc. shareholders approved Election of Class III Directors at the 2026-06-04 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2026-06-04
Exact text from the filing
Proposal 1. Election of Directors Name of Director Elected For Withheld Broker Non-Votes Diane Parks 44,060,724 14,620,308 11,097,548
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Kura Oncology, Inc. shareholders approved Approval of our Amended 2014 Plan at the 2026-06-04 meeting.
- Proposal
- equity plan
- Outcome
- passed
- Meeting
- 2026-06-04
Exact text from the filing
Proposal 5. Approval of our Amended 2014 Plan For Against Abstain Broker Non-Votes 48,402,820 10,099,296 178,916 11,097,548
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Kura Oncology, Inc. shareholders approved Advisory Vote on Executive Compensation at the 2026-06-04 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2026-06-04
Exact text from the filing
Proposal 3. Advisory Vote on Executive Compensation For Against Abstain Broker Non-Votes 48,783,834 1,141,854 8,755,344 11,097,548
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Kura Oncology, Inc. shareholders approved Ratification of the Appointment of Ernst & Young LLP as Independent Registered Public Accounting Firm at the 2026-06-04 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2026-06-04
Exact text from the filing
Proposal 2. Ratification of the Appointment of Independent Registered Public Accounting Firm For Against Abstain Broker Non-Votes 69,385,497 140,763 252,320 —
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.